Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 1;47(10):1750-1756.
doi: 10.2337/dc24-0540.

Early Dysglycemia Is Detectable Using Continuous Glucose Monitoring in Very Young Children at Risk of Type 1 Diabetes

Collaborators, Affiliations

Early Dysglycemia Is Detectable Using Continuous Glucose Monitoring in Very Young Children at Risk of Type 1 Diabetes

Aveni Haynes et al. Diabetes Care. .

Abstract

Objective: Continuous glucose monitoring (CGM) can detect early dysglycemia in older children and adults with presymptomatic type 1 diabetes (T1D) and predict risk of progression to clinical onset. However, CGM data for very young children at greatest risk of disease progression are lacking. This study aimed to investigate the use of CGM data measured in children being longitudinally observed in the Australian Environmental Determinants of Islet Autoimmunity (ENDIA) study from birth to age 10 years.

Research design and methods: Between January 2021 and June 2023, 31 ENDIA children with persistent multiple islet autoimmunity (PM Ab+) and 24 age-matched control children underwent CGM assessment alongside standard clinical monitoring. The CGM metrics of glucose SD (SDSGL), coefficient of variation (CEV), mean sensor glucose (SGL), and percentage of time >7.8 mmol/L (>140 mg/dL) were determined and examined for between-group differences.

Results: The mean (SD) ages of PM Ab+ and Ab- children were 4.4 (1.8) and 4.7 (1.9) years, respectively. Eighty-six percent of eligible PM Ab+ children consented to CGM wear, achieving a median (quartile 1 [Q1], Q3) sensor wear period of 12.5 (9.0, 15.0) days. PM Ab+ children had higher median (Q1, Q3) SDSGL (1.1 [0.9, 1.3] vs. 0.9 [0.8, 1.0] mmol/L; P < 0.001) and CEV (17.3% [16.0, 20.9] vs. 14.7% [12.9, 16.6]; P < 0.001). Percentage of time >7.8 mmol/L was greater in PM Ab+ children (median [Q1, Q3] 8.0% [4.4, 13.0] compared with 3.3% [1.4, 5.3] in Ab- children; P = 0.005). Mean SGL did not differ significantly between groups (P = 0.10).

Conclusions: CGM is feasible and well tolerated in very young children at risk of T1D. Very young PM Ab+ children have increased SDSGL, CEV, and percentage of time >7.8 mmol/L, consistent with prior studies involving older participants.

PubMed Disclaimer

Conflict of interest statement

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Figures

None
Graphical abstract
Figure 1
Figure 1
Mean (SD) sensor glucose (A), mean CEV sensor glucose (B), mean sensor glucose (C), and mean percentage of time spent >7.8 mmol/L (>140 mg/dL) (D) at time of first CGM in PM Ab+ and age- and sex-matched (assigned at birth) Ab children. Solid line represents median value in each group for metric shown in figure. SGL, sensor glucose level.
Figure 2
Figure 2
Mean sensor glucose (mmol/L) (A) and percentage of CGM time spent >7.8 mmol/L (>140 mg/dL) (B) by hour of day at time of first CGM period in PM Ab+ and Ab children. Each row represents values for an individual study participant. SGL, sensor glucose level. *Child later diagnosed with clinical T1D.

References

    1. Besser REJ, Bell KJ, Couper JJ, et al. . ISPAD clinical practice consensus guidelines 2022: stages of type 1 diabetes in children and adolescents. Pediatr Diabetes 2022;23:1175–1187 - PubMed
    1. Insel RA, Dunne JL, Atkinson MA, et al. . Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 2015;38:1964–1974 - PMC - PubMed
    1. American Diabetes Association Professional Practice Committee . 2. Diagnosis and classification of diabetes: Standards of Care in Diabetes—2024. Diabetes Care 2024;47(Suppl. 1):S20–S42 - PMC - PubMed
    1. Ziegler AG, Rewers M, Simell O, et al. . Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013;309:2473–2479 - PMC - PubMed
    1. Tatovic D, Narendran P, Dayan CM. Author Correction: A perspective on treating type 1 diabetes mellitus before insulin is needed. Nat Rev Endocrinol 2023;19:371–370 - PubMed